Krystal Biotech KRYS
United StatesHealthcare · BiotechnologyUSD
392.11 USD (+20.8%)
9 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Krystal Biotech is a biotechnology company developing next-generation gene therapies for skin diseases, with its lead product approved for dystrophic epidermolysis bullosa.
Key points
from its scores- ✓Good share-price trend9.7
- ✓Very solid balance sheet9.4
- ✓Strong growth8.6
- ✕Little or no dividend1.5
- ✕Demanding valuation3.0
AI analysis
bottom line, main risk, context and newsHold, given strong growth and a solid financial position, but the demanding valuation and lack of dividends suggest waiting for a better entry point.
Krystal Biotech shows excellent financial health (9.42) with net cash and a 49% operating margin, and solid growth (8.62) with revenues up 24.1%. However, its valuation is very demanding (P/E 40.67, EV/EBITDA 44.01), which limits investment appeal despite strong momentum (9.7).
The main risk is dependence on the commercial success of its approved gene therapy and the progress of its pipeline, subject to FDA regulatory approval and competition in the gene therapy market.
Context and risks
Krystal Biotech operates in the biotechnology sector in the United States, where regulatory and governance risk is moderate. Its business model depends on the approval and reimbursement of gene therapies, a process subject to the FDA and drug pricing policies, adding a specific layer of risk to the sector.
Is Krystal Biotech stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 128% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 40.7 | 26.7 | +52% |
| EV / EBITDA | 44.0 | 14.5 | +204% |
| Price / book | 7.1 | 4.1 | +72% |
| Price / sales | 21.8 | 3.4 | +538% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.0 out of 10 (median for Healthcare: 4.7).
Average analyst target: 392.11 USD, +20.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 7.9 (sector 5.5), Growth 8.6 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 40.7
- Forward P/E
- 34.8
- EV / EBITDA
- 44.0
- Price / book
- 7.1
- Price / sales
- 21.8
- PEG
- 1.00
- Market cap
- 9.6B USD
- Enterprise value
- 8.8B USD
Profitability
- ROE
- 20.1%
- ROA
- 9.4%
- ROIC (approx.)
- 15.8%
- Gross margin
- 94.6%
- Operating margin
- 49.0%
- Net margin
- 54.8%
- Free cash flow
- 151.7M USD
- FCF yield
- 1.6%
- Cash conversion
- 76%
Solvency
- Total debt
- 8.9M USD
- Net debt
- −836.8M USD
- Cash
- 845.6M USD
- EBITDA
- 199.3M USD
- Net debt / EBITDA
- −4.20
- Debt / equity
- 0.65
- Current ratio
- 8.32
- Quick ratio
- 7.73
Growth
- Revenue growth
- +24.1%
- Earnings growth
- +38.8%
- EPS (TTM)
- 7.98 USD
- EPS (forward)
- 9.32 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.50
- Analyst consensus
- Strong buy (9)
- Target price
- 392.11 USD
- 52-week range
- 179.19 – 382.54
Recent news
All KRYS news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Krystal Biotech
Is Krystal Biotech stock cheap or expensive?
On P/E and EV / EBITDA, it trades 128% above the Healthcare median on average. Valuation score: 3.0 out of 10 (median for Healthcare: 4.7). Average analyst target: 392.11 USD, +20.8% versus the price. This is not investment advice.
What score does Krystal Biotech get on MeridIAn Screener?
It scores 6.5 out of 10, rank 547 of 2,130 (better than 72% of the companies analysed). Its strongest category is Momentum (9.7) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Krystal Biotech's P/E ratio?
Its P/E is 40.7: the share price equals 40.7 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 34.8.
How much is Krystal Biotech worth on the stock market?
Its market capitalisation is 9.6B USD and its enterprise value, debt included, is 8.8B USD.
How much debt does Krystal Biotech have?
It has more cash than debt: net cash of 836.8M USD.
Does Krystal Biotech pay a dividend?
It pays no dividend, or almost none.
How has Krystal Biotech stock performed over the last year?
It has risen 78.9% over the last year, excluding dividends. Over the last 52 weeks it has traded between 179.19 and 382.54 USD. Past performance does not guarantee future results.
What do analysts think of Krystal Biotech?
9 analysts cover it; their average recommendation is “Strong buy” and their average target is 392.11 USD (+20.8% versus the price). It is an estimate, not market data.